Targeting SLC7A11 has the potential to disrupt the distinctive metabolic weaknesses of cancer cells, enhance the sensitivity of conventional therapies, and ameliorate the immune microenvironment, rendering it a treatment strategy with expansive promise. The gene discussed is SLC7A11; the disease is cancer.